A Phase 2 interventional study of RVT-1401 in Graves' Ophthalmopathy, sponsored by Immunovant Sciences GmbH. Completed at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-24.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
This study's enrollment of 7 is below the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Browse Graves Ophthalmopathy studies →Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RVT-1401 680 milligrams (mg) weekly for two weeks followed by 340 mg weekly for four weeks, administered subcutaneously
Drug: RVT-1401
RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period
AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug and on or before the date of the last dose of study drug + 42 days, or had no recorded start date and the stop date was in between the date of the first dose and the last dose of study drug + 42 days. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
Time frame: from Baseline up to Week 6
Number of Participants With Clinically Significant Findings Related to Vital Signs
Clinical significance was determined by the investigator.
Time frame: up to Week 18
Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study
Abnormality was determined by the investigator.
Time frame: up to Week 18
Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs)
Clinical significance was determined by the investigator.
Time frame: up to Week 18
Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels
The serum levels of total IgG and IgG subclasses (1-4) were determined. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7, Week 6 and 7 combined) minus the Baseline value, divided by the Baseline value x 100. A negative percent change from Baseline represents clinical improvement.
Time frame: Baseline; Week 7; Week 6 and 7 combined
Mean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7
The serum levels of anti-TSHR antibodies were determined. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.
Time frame: Baseline; Week 7
Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7
The study eye was defined as the most severely affected eye at the Baseline visit. In the event that both eyes were affected the same, the right eye was deemed as the study eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.
Time frame: Baseline; Week 7
Number of Participants With an Overall Proptosis Response
Proptosis responders were defined as participants with a ≥2 mm reduction in study eye without deterioration (≥2 mm increase) in the fellow eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes.
Time frame: Up to Week 18
Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401
Pharmacokinetic (PK) parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.
Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Maximum Concentration (Cmax) of RVT-1401
PK parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.
Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Serum Concentration at the End of the Dosing Interval (Ctrough) of RVT-1401
Time frame: Week 2, Week 3, Week 4, Week 5, Week 6 Day 36, and Week 7
Number of Participants With Anti-RVT-1401 Antibody and Confirmed Anti-RVT-1401 Antibody at Week 7
The serum levels of anti-RVT-1401 antibodies were determined. In the initial analysis the samples with responses equal to or above the plate-specific cut-point were identified as potentially positive while those below the cut-point were considered negative. These potentially positive samples were reanalyzed in confirmatory assay. Samples with percent inhibition greater than or equal to the confirmatory cut-point were considered confirmed positive and those below were considered negative.
Time frame: Week 7
| Milestone | RVT-1401 |
|---|---|
| Started | 7 |
| Completed | 5 |
| Not completed | 2 |
| Withdrew: Participant moved | 1 |
| Withdrew: Unable to come to site due to covid 19 | 1 |
AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug and on or before the date of the last dose of study drug + 42 days, or had no recorded start date and the stop date was in between the date of the first dose and the last dose of study drug + 42 days. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
| Participants | RVT-1401 |
|---|---|
| TEAEs | 7 |
| SAEs | 0 |
| Treatment-related AEs | 6 |
| Deaths | 0 |
Clinical significance was determined by the investigator.
| Participants | RVT-1401 |
|---|---|
| Number of Participants With Clinically Significant Findings Related to Vital Signs | 0 |
Abnormality was determined by the investigator.
| Participants | RVT-1401 |
|---|---|
| Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study | 0 |
Clinical significance was determined by the investigator.
| Participants | RVT-1401 |
|---|---|
| Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs) | 0 |
The serum levels of total IgG and IgG subclasses (1-4) were determined. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7, Week 6 and 7 combined) minus the Baseline value, divided by the Baseline value x 100. A negative percent change from Baseline represents clinical improvement.
| Percent change | RVT-1401 |
|---|---|
| Total IgG (Week 6 and 7 combined) | -65.00 ± 10.78 |
| Total IgG (Week 7) | -64.83 ± 17.65 |
| IgG1 (Week 7) | -67.16 ± 18.89 |
| IgG2 (Week 7) | -56.91 ± 24.66 |
| IgG3 (Week 7) | -70.05 ± 21.71 |
| IgG4 (Week 7) | -61.28 ± 16.25 |
The serum levels of anti-TSHR antibodies were determined. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.
| international units/milliliter (IU/mL) | RVT-1401 |
|---|---|
| Baseline | 19.72 ± 15.073 |
| Week 7 | -10.59 ± 9.827 |
The study eye was defined as the most severely affected eye at the Baseline visit. In the event that both eyes were affected the same, the right eye was deemed as the study eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.
| millimeter (mm) | RVT-1401 |
|---|---|
| Baseline, study eye | 23.1 ± 3.34 |
| Change from Baseline to Week 7, study eye | -1.25 ± 1.50 |
| Baseline, non-study eye | 21.9 ± 3.63 |
| Change from Baseline to Week 7, non-study eye | -1.25 ± 0.96 |
Proptosis responders were defined as participants with a ≥2 mm reduction in study eye without deterioration (≥2 mm increase) in the fellow eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes.
| Participants | RVT-1401 |
|---|---|
| Number of Participants With an Overall Proptosis Response | 3 |
Pharmacokinetic (PK) parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.
No measurements were reported for this outcome.
PK parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.
No measurements were reported for this outcome.
| mg/L | RVT-1401 |
|---|---|
| Week 2 | 4.018 ± 5.9584 |
| Week 3 | 12.075 ± 14.6431 |
| Week 4 | 1.284 ± 2.3063 |
| Week 5 | 0.167 ± 0.1682 |
| Week 6 Day 36 | 0.660 ± 1.5529 |
| Week 7 | 0.077 ± 0.0381 |
The serum levels of anti-RVT-1401 antibodies were determined. In the initial analysis the samples with responses equal to or above the plate-specific cut-point were identified as potentially positive while those below the cut-point were considered negative. These potentially positive samples were reanalyzed in confirmatory assay. Samples with percent inhibition greater than or equal to the confirmatory cut-point were considered confirmed positive and those below were considered negative.
| Participants | RVT-1401 |
|---|---|
| Initial analysis: negative anti-RVT-1401 antibody | 5 |
| Initial analysis: potentially positive anti-RVT-1401 antibody | 2 |
| Confirmed analysis: negative anti-RVT-1401 antibody | 2 |
Collected over from Baseline up to Week 18. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RVT-1401 | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Event | RVT-1401 |
|---|---|
| Lacrimation increasedEye disorders | 2/7 |
| FatigueGeneral disorders | 2/7 |
| DizzinessNervous system disorders | 2/7 |
| PalpitationsCardiac disorders | 1/7 |
| Eye swellingEye disorders | 1/7 |
| Ocular hyperaemiaEye disorders | 1/7 |
| Swelling of eyelidEye disorders | 1/7 |
| KeratopathyEye disorders | 1/7 |
| Eye painEye disorders | 1/7 |
| Eye irritationEye disorders | 1/7 |
| Age, Continuous(Years) | RVT-1401 |
|---|---|
| Mean | 56.7 ± 14.9 |
| Sex: Female, Male(Participants) | RVT-1401 |
|---|---|
| Female | 4 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | RVT-1401 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | RVT-1401 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels(grams per liter (g/L)) | RVT-1401 |
|---|---|
| IgG | 11.29 ± 1.71 |
| IgG1 | 5.11 ± 1.11 |
| IgG2 | 3.74 ± 0.96 |
| IgG3 | 0.61 ± 0.35 |
| IgG4 | 0.49 ± 0.34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Feb 2020, 10 months.
Results were first posted in Jan 2022, 1 year 10 months after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HBM9161
Immunovant Sciences GmbH